In the Erlangen Corona Study, comprising more than 2000 subjects, the risk for developing antibodies against the new coronavirus was tested in patients with arthritis, colitis and psoriasis by the Deutsche Zentrum für Immuntherapie (DZI) and Collaborative Research Center (CRC) 1181. The results of this study were just published in Nature Communications.